Dendritic cells in dengue virus infection: Targets of virus replication and mediators of immunity

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Schmid, Michael A ^a   Diamond, Michael S ^b   Harris, Eva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody dependent enhancement; Dendritic cells; Dengue virus; Immune evasion; Innate immunity; Macrophages; Monocytes

Indexed keywords

ALPHA INTERFERON; CD209 ANTIGEN; FC RECEPTOR; LIPOCORTIN 5; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; AEDES AEGYPTI; ARTICLE; DENDRITIC CELL; DENGUE; DENGUE VIRUS; HUMAN; HYPOTENSION; IMMUNE EVASION; INNATE IMMUNITY; LANGERHANS CELL; LIVER; LUNG; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE REACTION; MONOCYTE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; SALIVA; SPLEEN; VIRUS REPLICATION;

EID: 84919470479     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00647     Document Type: Article

References (124)

1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science (2010) 327(5963):291-5. doi:10.1126/science.1183021
2. Hornung V, Hartmann R, Ablasser A, Hopfner KP. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol (2014) 14(8):521-8. doi:10.1038/nri3719
3. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 31:563-604. doi:10.1146/annurev-immunol-020711-074950
4. Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol (2012) 13(12):1145-54. doi:10.1038/ni.2467
5. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol (2007) 7(7):543-55. doi:10.1038/nri2103
6. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol (2009) 10(12):1237-44. doi:10.1038/ni.1822
7. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev (2010) 234(1):120-41. doi:10.1111/j.0105-2896.2009.00886.x
8. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol (2011) 29:163-83. doi:10.1146/annurev-immunol-031210-101345
9. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity (2008) 29(3):352-61. doi:10.1016/j.immuni.2008.09.002
10. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol (2011) 11(11):762-74. doi:10.1038/nri3070
11. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol (2009) 27:669-92. doi:10.1146/annurev.immunol.021908.132557
12. Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, Longhi MP, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell (2010) 143(3):416-29. doi:10.1016/j.cell.2010.09.039
13. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor [alpha]. J Exp Med (1994) 179:1109-18. doi:10.1084/jem.179.4.1109
14. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 176(6):1693-702. doi:10.1084/jem.176.6.1693
15. Sallusto F, Lanzavecchia A. Monocytes join the dendritic cell family. Cell (2010) 143(3):339-40. doi:10.1016/j.cell.2010.10.022
16. Leon B, Lopez-Bravo M, Ardavin C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity (2007) 26(4):519-31. doi:10.1016/j.immuni.2007.01.017
17. Nakano H, Lin KL, Yanagita M, Charbonneau C, Cook DN, Kakiuchi T, et al. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol (2009) 10(4):394-402. doi:10.1038/ni.1707
18. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (2010) 327(5966):656-61. doi:10.1126/science.1178331
19. Halstead SB. Dengue. Lancet (2007) 370(9599):1644-52. doi:10.1016/S0140-6736(07)61687-0
20. Pierson TC, Diamond MS. Flaviviruses. Sixth ed. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott Williams and Wilkins (2013).
21. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature (2013) 496(7446):504-7. doi:10.1038/nature12060
22. World Health Organization. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention, and Control. Second ed. Geneva: World Health Organization (1997).
23. Guzman MG, Kouri G, Martinez E, Bravo J, Riveron R, Soler M, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ (1987) 21(3):270-9.
24. Halstead SB. Immune enhancement of viral infection. Prog Allergy (1982) 31:301-64.
25. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 38(2):411-9.
26. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis (2002) 8(12):1474-9. doi:10.3201/eid0812.020170
27. Gagnon SJ, Ennis FA, Rothman AL. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol (1999) 73(5):3623-9.
28. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis (2011) 203(9):1282-91. doi:10.1093/infdis/jir012
29. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 110(22):E2046-53. doi:10.1073/pnas.1305227110
30. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 9(7):921-7. doi:10.1038/nm887
31. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A (2010) 107(39):16922-7. doi:10.1073/pnas.1010867107
32. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol (2011) 11(8):532-43. doi:10.1038/nri3014
33. Ribeiro JM, Francischetti IM. Role of arthropod saliva in blood feeding: sialome and post-sialome perspectives. Annu Rev Entomol (2003) 48:73-88. doi:10.1146/annurev.ento.48.060402.102812
34. Valenzuela JG. Exploring tick saliva: from biochemistry to 'sialomes' and functional genomics. Parasitology (2004) 129(Suppl):S83-94. doi:10.1017/S0031182004005189
35. Ader DB, Celluzzi C, Bisbing J, Gilmore L, Gunther V, Peachman KK, et al. Modulation of dengue virus infection of dendritic cells by Aedes aegypti saliva. Viral Immunol (2004) 17(2):252-65. doi:10.1089/0882824041310496
36. Cox J, Mota J, Sukupolvi-Petty S, Diamond MS, Rico-Hesse R. Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol (2012) 86(14):7637-49. doi:10.1128/JVI.00534-12
37. McCracken MK, Christofferson RC, Chisenhall DM, Mores CN. Analysis of early dengue virus infection in mice as modulated by Aedes aegypti probing. J Virol (2014) 88(4):1881-9. doi:10.1128/JVI.01218-13
38. Hall WC, Crowell TP, Watts DM, Barros VL, Kruger H, Pinheiro F, et al. Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg (1991) 45(4):408-17.
39. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis (2004) 189:1411-8. doi:10.1086/383043
40. Balsitis SJ, Coloma J, Castro G, Alava A, Flores D, McKerrow JH, et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg (2009) 80:416-24.
41. Aye KS, Charngkaew K, Win N, Wai KZ, Moe K, Punyadee N, et al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol (2014) 45(6):1221-33. doi:10.1016/j.humpath.2014.01.022
42. Durbin A, Vargas MJ, Thumar B, Hammond SN, Gordon G, Rocha C, et al. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology (2008) 376:429-35. doi:10.1016/j.virol.2008.03.028
43. Shresta S, Kyle JL, Snider HM, Basanavapatna M, Beatty R, Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T and B cell-dependent immunity is less critical. J Virol (2004) 78:2701-10. doi:10.1128/JVI.78.6.2701-2710.2004
44. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. A murine model for dengue lethal disease with increased vascular permeability. J Virol (2006) 80:10208-17. doi:10.1128/JVI.00062-06
45. Kyle JL, Balsitis SB, Zhang L, Beatty PR, Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology (2008) 380:296-303. doi:10.1016/j.virol.2008.08.008
46. Orozco S, Schmid MA, Parameswaran P, Lachica R, Henn MR, Beatty R, et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol (2012) 93(Pt 10):2152-7. doi:10.1099/vir.0.045088-0
47. Kyle JL, Beatty PR, Harris E. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis (2007) 195(12):1808-17. doi:10.1086/518007
48. Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, Schul W. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur J Immunol (2009) 39(10):2809-21. doi:10.1002/eji.200939389
49. Prestwood TR, May MM, Plummer EM, Morar MM, Yauch LE, Shresta S. Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice. J Virol (2012) 86(22):12138-47. doi:10.1128/JVI.00375-12
50. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW, et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol (2001) 166:1499-506. doi:10.4049/jimmunol.166.3.1499
51. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol (2008) 82:3939-51. doi:10.1128/JVI.02484-07
52. Kwan WH, Navarro-Sanchez E, Dumortier H, Decossas M, Barreto dos Santos F, Fridman HW, et al. Dermal-type macrophages show resistance to dengue virus infection despite CD209/DC-SIGN expression. PLoS Negl Trop Dis (2008) 2:e311. doi:10.1371/journal.pntd.0000311
53. Schmid MA, Harris E. Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog (2014) 10(12):e1004541. doi:10.1371/journal.ppat.1004541
54. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol (2002) 2(2):77-84. doi:10.1038/nri827
55. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 197:823-9. doi:10.1084/jem.20021840
56. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Vierelizier JL, et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 4(7):723-9. doi:10.1038/sj.embor.embor866
57. Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, Xiao C, et al. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell (2006) 124(3):485-93. doi:10.1016/j.cell.2005.11.042
58. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med (2000) 6(7):816-20. doi:10.1038/77553
59. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol (2001) 75:3501-8. doi:10.1128/JVI.75.8.3501-3508.2001
60. Lozach PY, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier JL, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem (2005) 280(25):23698-708. doi:10.1074/jbc.M504337200
61. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, et al. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology (2009) 383(2):207-15. doi:10.1016/j.virol.2008.10.022
62. Miller JL, deWet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog (2008) 8:e17. doi:10.1371/journal.ppat.0040017
63. Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet (2005) 37(5):507-13. doi:10.1038/ng1550
64. Limon-Flores AY, Perez-Tapia M, Estrada-Garcia I, Vaughan G, Escobar-Gutierrez A, Calderon-Amador J, et al. Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. Int J Exp Pathol (2005) 86(5):323-34. doi:10.1111/j.0959-9673.2005.00445.x
65. Cerny D, Haniffa M, Shin A, Bigliardi P, Tan BK, Lee B, et al. Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog (2014) 10(12):e1004548. doi:10.1371/journal.ppat.1004548
66. Dejnirattisai W, Webb AI, Chan V, Jumnainsong A, Davidson A, Mongkolsapaya J, et al. Lectin switching during dengue virus infection. J Infect Dis (2011) 203(12):1775-83. doi:10.1093/infdis/jir173
67. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med (1977) 146(1):201-17. doi:10.1084/jem.146.1.201
68. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol (2008) 80(1):134-46. doi:10.1002/jmv.21051
69. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, et al. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol (2007) 81(24):13325-34. doi:10.1128/JVI.01568-07
70. Srikiatkhachorn A, Wichit S, Gibbons RV, Green S, Libraty DH, Endy TP, et al. Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status. PLoS One (2012) 7(12):e51335. doi:10.1371/journal.pone.0051335
71. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity (2006) 24(1):19-28. doi:10.1016/j.immuni.2005.11.010
72. Schlesinger JJ, Chapman SE. Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus. Virology (1999) 260(1):84-8. doi:10.1006/viro.1999.9816
73. Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol (2006) 80(20):10128-38. doi:10.1128/JVI.00792-06
74. Boonnak K, Slike BM, Donofrio GC, Marovich MA. Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol (2013) 190(11):5659-65. doi:10.4049/jimmunol.1203052
75. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, Lim AP, et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A (2011) 108(30):12479-84. doi:10.1073/pnas.1106568108
76. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol (1984) 120(5):653-69.
77. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 181:2-9. doi:10.1086/315215
78. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis (2002) 185(9):1213-21. doi:10.1086/340365
79. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol (2013) 158(7):1445-59. doi:10.1007/s00705-013-1645-3
80. Loke H, Bethell D, Phuong CX, Day N, White N, Farrar J, et al. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. Am J Trop Med Hyg (2002) 67(1):102-6.
81. Garcia G, Sierra B, Perez AB, Aguirre E, Rosado I, Gonzalez N, et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg (2010) 82(6):1153-6. doi:10.4269/ajtmh.2010.09-0353
82. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 6(2):e1000790. doi:10.1371/journal.ppat.1000790
83. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe (2010) 7(2):128-39. doi:10.1016/j.chom.2010.01.004
84. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology (2012) 429(1):12-20. doi:10.1016/j.virol.2012.03.003
85. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, et al. Therapeutic efficacy of antibodies lacking Fcgamma receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 9(2):e1003157. doi:10.1371/journal.ppat.1003157
86. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 8(3):271-83. doi:10.1016/j.chom.2010.08.007
87. Brien JD, Sukupolvi-Petty S, Williams KL, Lam CY, Schmid MA, Johnson S, et al. Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol (2013) 87(13):7747-53. doi:10.1128/JVI.00327-13
88. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140(6):805-20. doi:10.1016/j.cell.2010.01.022
89. Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, Libraty DH. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol (2006) 177(10):7114-21. doi:10.4049/jimmunol.177.10.7114
90. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, Liu DX. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis (2011) 5(1):e926. doi:10.1371/journal.pntd.0000926
91. Kurane I, Ennis FA. Induction of interferon alpha from human lymphocytes by autologous, dengue virus-infected monocytes. J Exp Med (1987) 166(4):999-1010. doi:10.1084/jem.166.4.999
92. Kurane I, Ennis FA. Production of interferon alpha by dengue virus-infected human monocytes. J Gen Virol (1988) 69(Pt 2):445-9. doi:10.1099/0022-1317-69-2-445
93. Gandini M, Gras C, Azeredo EL, Pinto LM, Smith N, Despres P, et al. Dengue virus activates membrane TRAIL relocalization and IFN-alpha production by human plasmacytoid dendritic cells in vitro and in vivo. PLoS Negl Trop Dis (2013) 7(6):e2257. doi:10.1371/journal.pntd.0002257
94. Pichyangkul S, Endy TP, Kalayanarooj S, Nisalak A, Yongvanitchit K, Green S, et al. A blunted blood plasmacytoid dendritic cell response to an acute systemic viral infection is associated with increased disease severity. J Immunol (2003) 171(10):5571-8. doi:10.4049/jimmunol.171.10.5571
95. Decembre E, Assil S, Hillaire ML, Dejnirattisai W, Mongkolsapaya J, Screaton GR, et al. Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells. PLoS Pathog (2014) 10(10):e1004434. doi:10.1371/journal.ppat.1004434
96. Chen RF, Yang KD, Wang L, Liu JW, Chiu CC, Cheng JT. Different clinical and laboratory manifestations between dengue haemorrhagic fever and dengue fever with bleeding tendency. Trans R Soc Trop Med Hyg (2007) 101(11):1106-13. doi:10.1016/j.trstmh.2007.06.019
97. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, Dung NT, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis (2007) 195(8):1097-107. doi:10.1086/512162
98. Popper SJ, Gordon A, Liu M, Balmaseda A, Harris E, Relman DA. Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. PLoS Negl Trop Dis (2012) 6(12):e1966. doi:10.1371/journal.pntd.0001966
99. Yu CY, Chang TH, Liang JJ, Chiang RL, Lee YL, Liao CL, et al. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog (2012) 8(6):e1002780. doi:10.1371/journal.ppat.1002780
100. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog (2012) 8(10):e1002934. doi:10.1371/journal.ppat.1002934
101. Schoggins JW. Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol (2014) 6:40-6. doi:10.1016/j.coviro.2014.03.006
102. Ho LJ, Hung LF, Weng CY, Wu WL, Chou P, Lin YL, et al. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J Immunol (2005) 174(12):8163-72. doi:10.4049/jimmunol.174.12.8163
103. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol (2009) 83(11):5408-18. doi:10.1128/JVI.02188-08
104. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J Infect Dis (2009) 200(8):1261-70. doi:10.1086/605847
105. Morrison J, Laurent-Rolle M, Maestre AM, Rajsbaum R, Pisanelli G, Simon V, et al. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog (2013) 9(3):e1003265. doi:10.1371/journal.ppat.1003265
106. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 100(24):14333-8. doi:10.1073/pnas.2335168100
107. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 74:4957-66. doi:10.1128/JVI.74.17.7814-7823.2000
108. Diamond MS, Harris E. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology (2001) 289:297-311. doi:10.1006/viro.2001.1114
109. Chase AJ, Medina FA, Munoz-Jordan JL. Impairment of CD4+ T cell polarization by dengue virus-infected dendritic cells. J Infect Dis (2011) 203(12):1763-74. doi:10.1093/infdis/jir197
110. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis (2010) 10(10):712-22. doi:10.1016/S1473-3099(10)70166-3
111. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol (2007) 88(Pt 2):365-75. doi:10.1099/vir.0.82537-0
112. Modhiran N, Kalayanarooj S, Ubol S. Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis (2010) 4(12):e924. doi:10.1371/journal.pntd.0000924
113. Chan KR, Ong EZ, Tan HC, Zhang SL, Zhang Q, Tang KF, et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci U S A (2014) 111(7):2722-7. doi:10.1073/pnas.1317454111
114. Sun P, Celluzzi CM, Marovich M, Subramanian H, Eller M, Widjaja S, et al. CD40 ligand enhances dengue viral infection of dendritic cells: a possible mechanism for T cell-mediated immunopathology. J Immunol (2006) 177(9):6497-503. doi:10.4049/jimmunol.177.9.6497
115. Wong KL, Chen W, Balakrishnan T, Toh YX, Fink K, Wong SC. Susceptibility and response of human blood monocyte subsets to primary dengue virus infection. PLoS One (2012) 7(5):e36435. doi:10.1371/journal.pone.0036435
116. Palmer DR, Sun P, Celluzzi C, Bisbing J, Pang S, Sun W, et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol (2005) 79(4):2432-9. doi:10.1128/JVI.79.4.2432-2439.2005
117. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol (2006) 311:17-58. doi:10.1007/3-540-32636-7-2
118. Dejnirattisai W, Duangchinda T, Lin CL, Vasanawathana S, Jones M, Jacobs M, et al. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol (2008) 181(9):5865-74. doi:10.4049/jimmunol.181.9.5865
119. Nightingale ZD, Patkar C, Rothman AL. Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. J Leukoc Biol (2008) 84(4):1028-38. doi:10.1189/jlb.0208105
120. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol (2010) 84(9):4845-50. doi:10.1128/JVI.02514-09
121. Sun P, Beckett C, Danko J, Burgess T, Liang Z, Kochel T, et al. A dendritic cell-based assay for measuring memory T cells specific to dengue envelope proteins in human peripheral blood. J Virol Methods (2011) 173(2):175-81. doi:10.1016/j.jviromet.2011.01.023
122. Sun P, Garcia J, Comach G, Vahey MT, Wang Z, Forshey BM, et al. Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity. PLoS Negl Trop Dis (2013) 7(7):e2298. doi:10.1371/journal.pntd.0002298
123. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 12(8):557-69. doi:10.1038/nri3254
124. Haniffa M, Collin M, Ginhoux F. Identification of human tissue cross-presenting dendritic cells: a new target for cancer vaccines. Oncoimmunology (2013) 2(3):e23140. doi:10.4161/onci.23140